On Thursday the Department of Health (DHSC) announced its procurement exercise for an express freight service contract to deliver medicines and medical supplies into the country in the event of a no-deal Brexit. This new £25m contract is intended to deliver small parcels of medicines or medical products on a 24-hour basis, with additional provision to move larger pallet quantities on a two to four-day basis. The contract will run for 12 months, with a possible further 12-month extension. The contract notice has been published in the Official Journal of the European Union and potential bidders have until August 21 to submit proposals, with the successful provider or providers likely to be announced in September.
The BIA has published a new guide for members on the supplementary protection certificate (SPC) manufacturing waiver, which has recently been introduced in the EU. Here, the lead author, Andrew Hutchison, explains why the BIA’s IP Advisory Committee has produced the guide.
In this fifth edition in our blog series on the 2019 Spending Review, BIA’s Policy and Public Affairs Manager Eric Johnsson looks at what the recently announced fast-tracked spending round means for our sector.
It feels like the new Government has been making an announcement a day this August! My blog this week highlights the seven key announcements for our sector in the last week, so sorry it’s longer and denser than normal, especially if you are picking this up after a holiday.
Many of you will have seen the Government announcement last week that the Chancellor Sajid Javid has released an extra £2 billion to prepare for a no-deal Brexit. Out of this, £434 million is earmarked to be spent on medicines and medical products and while this is a significant amount of money, we now need detail of how this money will be spent and whether this is indeed new money.
Our new Prime Minister has now been in Number 10 for six days and his government has quickly taken shape. Commentators have been shocked by the “brutal” shake-up of the Cabinet as Boris Johnson has sought to build a team that is 100% committed to his agenda. That agenda is characterised by Brexit, but beyond that, there are positive signs that Boris will be backing biotech
Cell and gene therapies, otherwise known as advanced therapy medicinal products (ATMPs), have been developing quickly, revolutionising patient treatment across a range of conditions, but particularly leukaemia and lymphoma. That potential is now being realised across the disease landscape and the UK is playing a leading role in making that a reality.
Last week, the Home Office published the 2018 statistics of scientific procedures on living animals in Great Britain.
The statistics show that last year, 3.52 million procedures involving living animals were carried out in Great Britain. This is a decrease of 7% from 2017, and the lowest number of procedures since 2007. Nearly half of these procedures were carried out by ten organisations, including the Medical Research Council, the Francis Crick Institute and the University of Oxford.